IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH PEMBROLIZUMAB IN DMMR/MSI-H COLORECTAL CANCER: A SINGLE ARM SAFETY META-ANALYSIS

Authors

Joshi Simran, Department of Medicine, Yale New Haven Health System, Bridgeport, CT
Saman Javid, Jaipur National University, Jaipur, Rajasthan, India
Gaurav Sharma, Jaipur National University, Jaipur, Rajasthan, India
Corinne Caissie, Department of Medicine, Yale New Haven Health System, Bridgeport, CT
Armando Dominguez-Diaz, Department of Medicine, Yale New Haven Health System

Document Type

Conference Proceeding

Abstract

Pembrolizumab, a PD-1 checkpoint inhibitor, enhances immune response and has proven effective against various cancers, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.

Clinical trials have also shown its efficacy in treating various types of cancers with different mismatch-repair statuses. However, the spectrum and frequency of immune-related adverse events (irAEs) in the dMMR (deficient mismatch repair) / MSI-H (microsatellite instability-high) colorectal cancer remain underexplored.

Therefore, this meta-analysis aims to evaluate pembrolizumab's safety profile in this colorectal cancer subset.

Publication Date

5-2025

Recommended Citation

Simran, Joshi; Javid, Saman; Sharma, Gaurav; Caissie, Corinne; and Dominguez-Diaz, Armando, "IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH PEMBROLIZUMAB IN DMMR/MSI-H COLORECTAL CANCER: A SINGLE ARM SAFETY META-ANALYSIS" (2025). Posters. 88.
https://scholar.bridgeporthospital.org/poster_presentations/88